Amedeo Smart

Free Medical Literature Service


 

Amedeo

Hepatitis C

  Free Subscription

Articles published in
PLoS One
    January 2022
  1. MAWATARI S, Kumagai K, Oda K, Tabu K, et al
    Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus.
    PLoS One. 2022;17:e0262267.
    >> Share

  2. BOODRAM B, Mackesy-Amiti ME, Khanna A, Brickman B, et al
    People who inject drugs in metropolitan Chicago: A meta-analysis of data from 1997-2017 to inform interventions and computational modeling toward hepatitis C microelimination.
    PLoS One. 2022;17:e0248850.
    >> Share

  3. BALIASHVILI D, Averhoff F, Kasradze A, Salyer SJ, et al
    Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey.
    PLoS One. 2022;17:e0262935.
    >> Share

  4. MORSICA G, Galli L, Messina E, Castagna A, et al
    Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV.
    PLoS One. 2022;17:e0262917.
    >> Share

  5. PRINSENBERG T, Illidge J, Zantkuijl P, Bedert M, et al
    Usability, acceptability, and self-reported impact of an innovative hepatitis C risk reduction intervention for men have sex with men: A mixed methods study.
    PLoS One. 2022;17:e0263654.
    >> Share

  6. LIM SH, Lee S, Lee YB, Lee CH, et al
    Increased prevalence of transfusion-transmitted diseases among people with tattoos: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0262990.
    >> Share

  7. SHRESTHA LB, Yadav GK, Pradhan S, Sharma A, et al
    Co-infection of Hepatitis B and Hepatitis C among HIV-infected patients: A cross-sectional study from tertiary care hospital of eastern Nepal.
    PLoS One. 2022;17:e0264791.
    >> Share

  8. TATARA E, Gutfraind A, Collier NT, Echevarria D, et al
    Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
    PLoS One. 2022;17:e0264983.
    >> Share

  9. TRAN L, Jung J, Feldman R, Riley T 3rd, et al
    Disparities in the quality of care for chronic hepatitis C among Medicare beneficiaries.
    PLoS One. 2022;17:e0263913.
    >> Share

  10. NAGORNYKH AM, Tyumentseva MA, Tyumentsev AI, Akimkin VG, et al
    Protocol for chronic hepatitis B virus infection mouse model development by patient-derived orthotopic xenografts.
    PLoS One. 2022;17:e0264266.
    >> Share

  11. TAKAURA K, Kurosaki M, Inada K, Kirino S, et al
    The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy.
    PLoS One. 2022;17:e0264075.
    >> Share

  12. LIN MC, Dai CY, Huang CF, Yeh ML, et al
    Itemization difference of patient-reported outcome in patients with chronic liver disease.
    PLoS One. 2022;17:e0264348.
    >> Share

  13. YAZDANI K, Dolguikh K, Zhang W, Shayegi-Nik S, et al
    Knowledge of hepatitis C and awareness of reinfection risk among people who successfully completed direct acting antiviral therapy.
    PLoS One. 2022;17:e0265811.
    >> Share


  14. Expression of Concern: Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation.
    PLoS One. 2022;17:e0266498.
    >> Share


  15. Expression of Concern: SH2 Modified STAT1 Induces HLA-I Expression and Improves IFN-gamma Signaling in IFN-alpha Resistant HCV Replicon Cells.
    PLoS One. 2022;17:e0266497.
    >> Share

  16. CHANDRA DEB L, Hove H, Miller TK, Pinks K, et al
    Epidemiology of Hepatitis C virus infection among incarcerated populations in North Dakota.
    PLoS One. 2022;17:e0266047.
    >> Share

  17. ROJAS ROJAS T, Poizot-Martin I, Rey D, Duvivier C, et al
    Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France.
    PLoS One. 2022;17:e0261069.
    >> Share

  18. SEYOUM E, Demissie M, Worku A, Mulu A, et al
    HIV, hepatitis B virus, and hepatitis C virus co-infection among HIV positives in antiretroviral treatment program in selected hospitals in Addis Ababa: A retrospective cross-sectional study.
    PLoS One. 2022;17:e0267230.
    >> Share

  19. AUMA AWN, Kowal C, Shive CL, Lange A, et al
    Transient elastography score is elevated during rheumatoid factor-positive chronic hepatitis C virus infection and rheumatoid factor decline is highly variable over the course of direct-acting antiviral therapy.
    PLoS One. 2022;17:e0267512.
    >> Share

  20. MABUNDA N, Augusto O, Zicai AF, Duaja A, et al
    Nucleic acid testing identifies high prevalence of blood borne viruses among approved blood donors in Mozambique.
    PLoS One. 2022;17:e0267472.
    >> Share

  21. TAHERKHANI R, Farshadpour F
    Prevalence, genotype distribution and mutations of hepatitis B virus and the associated risk factors among pregnant women residing in the northern shores of Persian Gulf, Iran.
    PLoS One. 2022;17:e0265063.
    >> Share

  22. FACENTE SN, Grinstein R, Bruhn R, Kaidarova Z, et al
    Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019.
    PLoS One. 2022;17:e0267902.
    >> Share

  23. MANZOOR S, Khalid M, Idrees M
    P2X4 receptors mediate induction of antioxidants, fibrogenic cytokines and ECM transcripts; in presence of replicating HCV in in vitro setting: An insight into role of P2X4 in fibrosis.
    PLoS One. 2022;17:e0259727.
    >> Share

  24. BATSAIKHAN B, Huang CI, Yeh ML, Huang CF, et al
    Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients.
    PLoS One. 2022;17:e0268180.
    >> Share

  25. O'DONNELL A, Pham N, Battisti L, Epstein R, et al
    Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection.
    PLoS One. 2022;17:e0268478.
    >> Share

  26. MARQUEZ LK, Ingiliz P, Boesecke C, Krznaric I, et al
    Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis.
    PLoS One. 2022;17:e0267853.
    >> Share

  27. ULLAH A, Yu X, Odenthal M, Meemboor S, et al
    Circulating microRNA-122 in HCV cirrhotic patients with high frequency of genotype 3.
    PLoS One. 2022;17:e0268526.
    >> Share

  28. BOFF DA COSTA R, Boff Costa M, Longo L, Miotto DE, et al
    Correction: Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications.
    PLoS One. 2022;17:e0269049.
    >> Share

  29. KENFACK-MOMO R, Kenmoe S, Takuissu GR, Ebogo-Belobo JT, et al
    Epidemiology of hepatitis B virus and/or hepatitis C virus infections among people living with human immunodeficiency virus in Africa: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0269250.
    >> Share

  30. CHUAYPEN N, Siripongsakun S, Hiranrat P, Tanpowpong N, et al
    Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants.
    PLoS One. 2022;17:e0269641.
    >> Share

  31. MADEIRA F, Costa-Lopes R, Do Bu EA, Tato Marinho R, et al
    The role of stereotypical information on medical judgements for black and white patients.
    PLoS One. 2022;17:e0268888.
    >> Share

  32. RAU M, Buggisch P, Mauss S, Boeker KHW, et al
    Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry.
    PLoS One. 2022;17:e0264741.
    >> Share

  33. CHEN YC, Wang HW, Huang YT, Jiang MY, et al
    Association of hepatitis C virus infection status and genotype with kidney disease risk: A population-based cross-sectional study.
    PLoS One. 2022;17:e0271197.
    >> Share

  34. CAIROLI V, De Matteo E, Casciato P, Ameigeiras B, et al
    The performance of soluble CD163 as a non-invasive biomarker of liver damage in chronically HCV and HCV/HIV infected subjects.
    PLoS One. 2022;17:e0270911.
    >> Share

  35. SHIRAI K, Hikita H, Sakane S, Narumi R, et al
    Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.
    PLoS One. 2022;17:e0271020.
    >> Share

  36. SAHIBZADA KI, Ganova-Raeva L, Dimitrova Z, Ramachandran S, et al
    Hepatitis C virus transmission cluster among injection drug users in Pakistan.
    PLoS One. 2022;17:e0270910.
    >> Share

  37. MATA-MARIN JA, de Pablos-Leal AA, Mauss S, Arroyo-Anduiza CI, et al
    Risk factors for HCV transmission in HIV-positive men who have sex with men in Mexico.
    PLoS One. 2022;17:e0269977.
    >> Share

  38. LAHOOD A, Rahman R, McKenna L, Frick M, et al
    Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different.
    PLoS One. 2022;17:e0271102.
    >> Share

  39. VAKILI J, Sizemore L, Rebeiro PF, Tyndall B, et al
    Assessment of Tennessee's county-level vulnerability to hepatitis C virus and HIV outbreaks using socioeconomic, healthcare, and substance use indicators.
    PLoS One. 2022;17:e0270891.
    >> Share

  40. SCHORR O, Blach S, Thurnheer C, Ruis C, et al
    Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
    PLoS One. 2022;17:e0272518.
    >> Share

  41. LU YH, Lu CK, Chen CH, Hsieh YY, et al
    Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting.
    PLoS One. 2022;17:e0272567.
    >> Share

  42. TESFU MA, Belay NB, Habtemariam TT
    Co-infection of HIV or HCV among HBsAg positive delivering mothers and its associated factors in governmental hospitals in Addis Ababa, Ethiopia: A cross-sectional study.
    PLoS One. 2022;17:e0273300.
    >> Share

  43. STOPKA TJ, Yaghi O, Li M, Paintsil E, et al
    Molecular and spatial epidemiology of HCV among people who inject drugs in Boston, Massachusetts.
    PLoS One. 2022;17:e0266216.
    >> Share

  44. CELESTE-VILLALVIR A, Wilkerson JM, Markham C, Rodriguez L, et al
    A qualitative investigation of organizational challenges and facilitators to screening individuals experiencing homelessness for hepatitis C virus (HCV) in Houston, Texas.
    PLoS One. 2022;17:e0273302.
    >> Share

  45. BEHMARD E, Abdulabbas HT, Abdalkareem Jasim S, Najafipour S, et al
    Design of a novel multi-epitope vaccine candidate against hepatitis C virus using structural and nonstructural proteins: An immunoinformatics approach.
    PLoS One. 2022;17:e0272582.
    >> Share

  46. NARTEY YA, Antwi SO, Bockarie AS, Hiebert L, et al
    Mortality burden due to liver cirrhosis and hepatocellular carcinoma in Ghana; prevalence of risk factors and predictors of poor in-hospital survival.
    PLoS One. 2022;17:e0274544.
    >> Share

  47. KACEM M, Dhouib W, Bennasrallah C, Zemni I, et al
    Occupational exposure to hepatitis C virus infection and associated factors among healthcare workers in Fattouma Bourguiba University Hospital, Tunisia.
    PLoS One. 2022;17:e0274609.
    >> Share

  48. YOKOKAWA H, Shinohara M, Teraoka Y, Imamura M, et al
    Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants.
    PLoS One. 2022;17:e0274283.
    >> Share

  49. LEE AW, Jacobs W, Tran M, Nguyen B, et al
    Sociodemographic characteristics associated with hepatitis C virus infection in Vietnamese Americans: A cross-sectional analysis of community screening data.
    PLoS One. 2022;17:e0275210.
    >> Share

    January 2021
  50. HEFFERNAN A, Ma Y, Nayagam S, Chan P, et al
    Economic and epidemiological evaluation of interventions to reduce the burden of hepatitis C in Yunnan province, China.
    PLoS One. 2021;16:e0245288.
    >> Share

  51. HUANG YC, Huang CF, Liu SF, Liu HY, et al
    The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan.
    PLoS One. 2021;16:e0246376.
    >> Share

  52. LIN CP, Liang PC, Huang CI, Yeh ML, et al
    Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals.
    PLoS One. 2021;16:e0245479.
    >> Share

  53. BAKER JD, Uhrich RL, Kraemer GC, Love JE, et al
    A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.
    PLoS One. 2021;16:e0245962.
    >> Share

  54. BOFF DA COSTA R, Boff Costa M, Longo L, Miotto DE, et al
    Direct antiviral agents for hepatitis C and drug interaction risk: A retrospective cohort study with real and simulated data on medication interaction, prevalence of comorbidities and comedications.
    PLoS One. 2021;16:e0245767.
    >> Share

  55. KWON JA, Chambers GM, Luciani F, Zhang L, et al
    Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis.
    PLoS One. 2021;16:e0245896.
    >> Share

  56. MAJD JABBARI S, Maajani K, Merat S, Poustchi H, et al
    An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease.
    PLoS One. 2021;16:e0246594.
    >> Share

  57. ANWAR WA, El Gaafary M, Girgis SA, Rafik M, et al
    Hepatitis C virus infection and risk factors among patients and health-care workers of Ain Shams University hospitals, Cairo, Egypt.
    PLoS One. 2021;16:e0246836.
    >> Share

  58. GRUBYTE S, Urboniene J, Nedzinskiene L, Jelinskaite A, et al
    Prevalence, incidence and residual risk of transfusion transmitted viruses (HBV, HCV and HIV infections) in Lithuanian blood donors from 2004 to 2018: The incidence/window-period model study.
    PLoS One. 2021;16:e0246704.
    >> Share

  59. MUHLBACHER AC, Sadler A
    Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".
    PLoS One. 2021;16:e0245480.
    >> Share

  60. METWALLY AM, Elmosalami DM, Elhariri H, El Etreby LA, et al
    Accelerating Hepatitis C virus elimination in Egypt by 2030: A national survey of communication for behavioral development as a modelling study.
    PLoS One. 2021;16:e0242257.
    >> Share

  61. HO H, Janjua NZ, McGrail KM, Harrison M, et al
    The impact of public coverage of newer hepatitis C medications on utilization, adherence, and costs in British Columbia.
    PLoS One. 2021;16:e0247843.
    >> Share

  62. RAJHI M, Haddad-Boubaker S, Chouikha A, Bourquain D, et al
    Identification of two novel hepatitis C virus subtype 2 from Tunisia (2v and 2w).
    PLoS One. 2021;16:e0248249.
    >> Share

  63. MCINTOSH AT, Wei R, Ahn J, Aouizerat BE, et al
    A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women.
    PLoS One. 2021;16:e0247277.
    >> Share

  64. SUENAGA R, Suka M, Hirao T, Hidaka I, et al
    Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
    PLoS One. 2021;16:e0248748.
    >> Share

  65. HERNANDEZ CJ, Trujillo D, Sicro S, Meza J, et al
    High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California.
    PLoS One. 2021;16:e0249219.
    >> Share

  66. TONEN-WOLYEC S, Djang'eing'a RM, Batina-Agasa S, Kayembe Tshilumba C, et al
    Self-testing for HIV, HBV, and HCV using finger-stick whole-blood multiplex immunochromatographic rapid test: A pilot feasibility study in sub-Saharan Africa.
    PLoS One. 2021;16:e0249701.
    >> Share

  67. MIRZAZADEH A, Chen YH, Lin J, Burk K, et al
    Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco.
    PLoS One. 2021;16:e0249585.
    >> Share

  68. AHMED HR, Waly NGFM, Abd El-Baky RM, Yahia R, et al
    Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.
    PLoS One. 2021;16:e0249770.
    >> Share

  69. PONNUVEL S, Fletcher GJ, Anantharam R, Varughese S, et al
    Clinical utility of hepatitis C virus core antigen (HCVcAg) assay to identify active HCV infection in hemodialysis and renal transplant patients.
    PLoS One. 2021;16:e0250263.
    >> Share

  70. PALAYEW A, Schmidt AM, Saeed S, Cooper CL, et al
    Estimating an individual-level deprivation index for HIV/HCV coinfected persons in Canada.
    PLoS One. 2021;16:e0249836.
    >> Share

  71. KAARTINEN K, Vuoti S, Honkanen E, Loyttyniemi E, et al
    Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C.
    PLoS One. 2021;16:e0251392.
    >> Share

  72. LEE CY, Wu PH, Lu MW, Chen TC, et al
    High prevalence of unawareness of HCV infection status among both HCV-seronegative and seropositive people living with human immunodeficiency virus in Taiwan.
    PLoS One. 2021;16:e0251158.
    >> Share

  73. BUGGISCH P, Heiken H, Mauss S, Weber B, et al
    Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study.
    PLoS One. 2021;16:e0250833.
    >> Share

  74. IREKEOLA AA, Malek NA, Wada Y, Mustaffa N, et al
    Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0251673.
    >> Share

  75. BOBARDT M, Ramirez CM, Baum MM, Ure D, et al
    The combination of the NS5A and cyclophilin inhibitors results in an additive anti-HCV inhibition in humanized mice without development of resistance.
    PLoS One. 2021;16:e0251934.
    >> Share

  76. DIDIYA R, Gyenwali D, Pokhrel TN, Devkota S, et al
    Community led testing among people who inject drugs: A community centered model to find new cases of HIV and Hepatitis C in Nepal.
    PLoS One. 2021;16:e0252490.
    >> Share

  77. WURCEL AG, Reyes J, Zubiago J, Koutoujian PJ, et al
    "I'm not gonna be able to do anything about it, then what's the point?": A broad group of stakeholders identify barriers and facilitators to HCV testing in a Massachusetts jail.
    PLoS One. 2021;16:e0250901.
    >> Share

  78. PARK JS, Wong J, Cohen H
    Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications.
    PLoS One. 2021;16:e0252976.
    >> Share

  79. WYNN A, Tweeten S, McDonald E, Wooten W, et al
    The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018.
    PLoS One. 2021;16:e0251635.
    >> Share

  80. FLEISHER I, Geboy AG, Nichols W, Desale S, et al
    HIV testing in patients who are HCV positive: Compliance with CDC guidelines in a large healthcare system.
    PLoS One. 2021;16:e0252412.
    >> Share

  81. GAHRTON C, Hakansson A, Kaberg M, Jerkeman A, et al
    Mortality among amphetamine users with hepatitis C virus infection: A nationwide study.
    PLoS One. 2021;16:e0253710.
    >> Share

  82. TORO DM, Ramasawmy R, Silva Neto PV, Pereira GL, et al
    Inflammasome genes polymorphisms may influence the development of hepatitis C in the Amazonas, Brazil.
    PLoS One. 2021;16:e0253470.
    >> Share

  83. RAHMAN S, Wathington D, Waterboer T, Pawlita M, et al
    Seroprevalence of Chlamydia trachomatis, herpes simplex 2, Epstein-Barr virus, hepatitis C and associated factors among a cohort of men ages 18-70 years from three countries.
    PLoS One. 2021;16:e0253005.
    >> Share

  84. LIU HY, Lin YH, Lin PJ, Tsai PC, et al
    Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection.
    PLoS One. 2021;16:e0254028.
    >> Share

  85. LLORENS-REVULL M, Costafreda MI, Rico A, Guerrero-Murillo M, et al
    Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
    PLoS One. 2021;16:e0254243.
    >> Share

  86. BLOOM DE, Khoury A, Srinivasan V
    Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
    PLoS One. 2021;16:e0252764.
    >> Share

  87. PRENTOE J, Janitzek CM, Velazquez-Moctezuma R, Goksoyr L, et al
    Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens.
    PLoS One. 2021;16:e0255336.
    >> Share

  88. DEFANTE FERRETO LE, Guedes S, Braz Pauli F, Soligo Rovani S, et al
    Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study.
    PLoS One. 2021;16:e0255173.
    >> Share

  89. SINN DH, Kang D, Hong YS, Koh KC, et al
    Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study.
    PLoS One. 2021;16:e0255624.
    >> Share

  90. YUNIHASTUTI E, Hariyanto R, Sulaiman AS, Harimurti K, et al
    Hepatitis C continuum of care: Experience of integrative hepatitis C treatment within a human immunodeficiency virus clinic in Indonesia.
    PLoS One. 2021;16:e0256164.
    >> Share

  91. AHSAN A, Dar S, Hassan F, Ghafoor F, et al
    Characterization of linear epitope specificity of antibodies potentially contributing to spontaneous clearance of hepatitis C virus.
    PLoS One. 2021;16:e0256816.
    >> Share

  92. KOBAYASHI H, Joshita S, Akahane Y, Matsuzaki K, et al
    Protocol: Prospective observational study aiming for micro-elimination of hepatitis C virus in Nagawa town: The Nagawa Project.
    PLoS One. 2021;16:e0256711.
    >> Share

  93. CHEN YC, Li CH, Ko PH, Lee CC, et al
    Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals.
    PLoS One. 2021;16:e0256505.
    >> Share

  94. ATSUKAWA M, Tsubota A, Kondo C, Uchida-Kobayashi S, et al
    A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C.
    PLoS One. 2021;16:e0257166.
    >> Share

  95. KWON JA, Dore GJ, Hajarizadeh B, Alavi M, et al
    Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
    PLoS One. 2021;16:e0257369.
    >> Share

  96. MIZUNO K, Haga H, Okumoto K, Hoshikawa K, et al
    Intrahepatic distribution of nerve fibers and alterations due to fibrosis in diseased liver.
    PLoS One. 2021;16:e0249556.
    >> Share

  97. KONG L, Karns R, Shata MTM, Brown JL, et al
    The synthetic opioid fentanyl enhances viral replication in vitro.
    PLoS One. 2021;16:e0249581.
    >> Share

  98. WAKABAYASHI SI, Joshita S, Kimura K, Motoki H, et al
    Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease.
    PLoS One. 2021;16:e0249435.
    >> Share

  99. LEE SO, Lee JE, Lee S, Lee SH, et al
    Prevalence and patterns of illicit drug use in people with human immunodeficiency virus infection in Korea.
    PLoS One. 2021;16:e0249361.
    >> Share

  100. MAZHAR MKA, Finger F, Evers ES, Kuehne A, et al
    An outbreak of acute jaundice syndrome (AJS) among the Rohingya refugees in Cox's Bazar, Bangladesh: Findings from enhanced epidemiological surveillance.
    PLoS One. 2021;16:e0250505.
    >> Share

  101. AFANEH H, Straif-Bourgeois S, Oral E, Wennerstrom A, et al
    Louisiana Medicaid access for treatment and care for hepatitis C virus (LA-MATCH) project: A cross-sectional study protocol.
    PLoS One. 2021;16:e0257437.
    >> Share

  102. SAINE ME, Szymczak JE, Moore TM, Bamford LP, et al
    The impact of disease-related knowledge on perceptions of stigma among patients with Hepatitis C Virus (HCV) infection.
    PLoS One. 2021;16:e0258143.
    >> Share

  103. ELKARANSHAWY HA, Ezzat HM, Ibrahim NN
    Lyapunov function and global asymptotic stability for a new multiscale viral dynamics model incorporating the immune system response: Implemented upon HCV.
    PLoS One. 2021;16:e0257975.
    >> Share

  104. MREMI A, Yahaya JJ, Nyindo M, Mollel E, et al
    Transfusion-Transmitted Infections and associated risk factors at the Northern Zone Blood Transfusion Center in Tanzania: A study of blood donors between 2017 and 2019.
    PLoS One. 2021;16:e0249061.
    >> Share

  105. KLOK S, van Dulm E, Boyd A, Generaal E, et al
    Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections among undocumented migrants and uninsured legal residents in the Netherlands: A cross-sectional study, 2018-2019.
    PLoS One. 2021;16:e0258932.
    >> Share

  106. ADANE T, Getawa S
    The prevalence and associated factors of hepatitis B and C virus in hemodialysis patients in Africa: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0251570.
    >> Share

  107. FERRETO LED, Guedes SJKO, Pauli FB, Rovani SS, et al
    Correction: Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study.
    PLoS One. 2021;16:e0260179.
    >> Share

  108. ISRAR M, Ali F, Nawaz A, Idrees M, et al
    Seroepidemiology and associated risk factors of hepatitis B and C virus infections among pregnant women attending maternity wards at two hospitals in Swabi, Khyber Pakhtunkhwa, Pakistan.
    PLoS One. 2021;16:e0255189.
    >> Share

  109. TOWNSHEND-BULSON L, Roik E, Barbour Y, Bruden DJT, et al
    The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.
    PLoS One. 2021;16:e0260970.
    >> Share

  110. GARCIA-HEROLA A, Dominguez-Hernandez R, Casado MA
    Clinical and economic impact of an alert system in primary care for the detection of patients with chronic hepatitis C.
    PLoS One. 2021;16:e0260608.
    >> Share

  111. NERSESOV A, Gusmanov A, Crape B, Junusbekova G, et al
    Seroprevalence and risk factors for hepatitis B and hepatitis C in three large regions of Kazakhstan.
    PLoS One. 2021;16:e0261155.
    >> Share

  112. KAMALI I, Barnhart DA, Ndahimana JD, Noor K, et al
    Prevalence and associated risk factors for hepatitis B and C viruses among refugee populations living in Mahama, Rwanda: A cross-sectional study.
    PLoS One. 2021;16:e0257917.
    >> Share

  113. BITTY-ANDERSON AM, Ferre V, Gbeasor-Komlanvi FA, Tchankoni MK, et al
    Prevalence of hepatitis B and C among female sex workers in Togo, West Africa.
    PLoS One. 2021;16:e0259891.
    >> Share

    January 2020
  114. RIVERO-JUAREZ A, Guijo-Rubio D, Tellez F, Palacios R, et al
    Using machine learning methods to determine a typology of patients with HIV-HCV infection to be treated with antivirals.
    PLoS One. 2020;15:e0227188.
    >> Share

  115. TSAI WL, Wang CF, Cheng JS, Chen WC, et al
    Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience.
    PLoS One. 2020;15:e0227424.
    >> Share

  116. SHAO LN, Zhang ST, Wang N, Yu WJ, et al
    Platelet indices significantly correlate with liver fibrosis in HCV-infected patients.
    PLoS One. 2020;15:e0227544.
    >> Share

  117. GOOD SS, Moussa A, Zhou XJ, Pietropaolo K, et al
    Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus.
    PLoS One. 2020;15:e0227104.
    >> Share

  118. NUTINI MFR, Hunter J, Giron L, Pires AFNPC, et al
    HCV genotype profile in Brazil of mono-infected and HIV co-infected individuals: A survey representative of an entire country.
    PLoS One. 2020;15:e0227082.
    >> Share

  119. LIU GY, Tang O, Brotman DJ, Miller ER 3rd, et al
    Gamma gap thresholds and HIV, hepatitis C, and monoclonal gammopathy.
    PLoS One. 2020;15:e0224977.
    >> Share

  120. HUHN GD, Ramgopal M, Jain MK, Hinestrosa F, et al
    HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
    PLoS One. 2020;15:e0224875.
    >> Share

  121. SAINE ME, Moore TM, Szymczak JE, Bamford LP, et al
    Validation of a modified Berger HIV stigma scale for use among patients with hepatitis C virus (HCV) infection.
    PLoS One. 2020;15:e0228471.
    >> Share

  122. PATEL SV, Jayaweera DT, Althoff KN, Eron JJ, et al
    Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV.
    PLoS One. 2020;15:e0228847.
    >> Share

  123. LEE KS, Quintiliani L, Heinz A, Johnson NL, et al
    A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program.
    PLoS One. 2020;15:e0228767.
    >> Share

  124. CARVALHO-GOMES A, Cubells A, Pallares C, Hontangas V, et al
    A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area.
    PLoS One. 2020;15:e0228351.
    >> Share

  125. SIRINAWASATIEN A, Techasirioangkun T
    Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    PLoS One. 2020;15:e0229517.
    >> Share

  126. CASTRO R, Perazzo H, de Araujo LAMM, Gutierres IG, et al
    Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis.
    PLoS One. 2020;15:e0229143.
    >> Share

  127. LIN SF, Tung SY, Wei KL, Chen CH, et al
    Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C.
    PLoS One. 2020;15:e0229994.
    >> Share

  128. SCHMIDBAUER C, Schubert R, Schutz A, Schwanke C, et al
    Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.
    PLoS One. 2020;15:e0229239.
    >> Share

  129. KHAN HU, Khan S, Shah MA, Attaullah S, et al
    Pre-existing resistance associated polymorphisms to NS3 protease inhibitors in treatment naive HCV positive Pakistani patients.
    PLoS One. 2020;15:e0231480.
    >> Share

  130. DOMINGUEZ-RODRIGUEZ S, Prieto L, Fernandez McPhee C, Illan-Ramos M, et al
    Perinatal HCV Transmission Rate in HIV/HCV Coinfected women with access to ART in Madrid, Spain.
    PLoS One. 2020;15:e0230109.
    >> Share

  131. PAZGAN-SIMON M, Kukla M, Zuwala-Jagiello J, Derra A, et al
    Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
    PLoS One. 2020;15:e0227459.
    >> Share

  132. WILLIAMS SH, Levy A, Yates RA, Somaweera N, et al
    Discovery of Jogalong virus, a novel hepacivirus identified in a Culex annulirostris (Skuse) mosquito from the Kimberley region of Western Australia.
    PLoS One. 2020;15:e0227114.
    >> Share

  133. PRINSENBERG T, Rebers S, Boyd A, Zuure F, et al
    Dried blood spot self-sampling at home is a feasible technique for hepatitis C RNA detection.
    PLoS One. 2020;15:e0231385.
    >> Share

  134. CHIU SM, Tsai MC, Lin CY, Chen CH, et al
    Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment.
    PLoS One. 2020;15:e0231102.
    >> Share

  135. KRACHT PAM, Arends JE, Hoepelman AIM, Vervoort SCJM, et al
    The balancing perspective of hard-to-reach hepatitis C patients who were lost to follow-up: A qualitative study.
    PLoS One. 2020;15:e0230756.
    >> Share

  136. WEITZEL T, Rodriguez F, Noriega LM, Marcotti A, et al
    Hepatitis B and C virus infection among HIV patients within the public and private healthcare systems in Chile: A cross-sectional serosurvey.
    PLoS One. 2020;15:e0227776.
    >> Share

  137. WAKE T, Tateishi R, Fukumoto T, Nakagomi R, et al
    Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume.
    PLoS One. 2020;15:e0231836.
    >> Share

  138. WON YK, Kang KS, Gonzalez YS, Razavi H, et al
    A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    PLoS One. 2020;15:e0232186.
    >> Share

  139. PIECHA F, Ganssler JM, Ozga AK, Wehmeyer MH, et al
    Treatment and re-treatment results of HCV patients in the DAA era.
    PLoS One. 2020;15:e0232773.
    >> Share

  140. AKHTAR S, Nasir JA, Usman M, Sarwar A, et al
    The prevalence of hepatitis C virus in hemodialysis patients in Pakistan: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0232931.
    >> Share

  141. NGUYEN DT, Tran TTT, Nghiem NM, Le PT, et al
    Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
    PLoS One. 2020;15:e0233446.
    >> Share

  142. HE L, Yuan H, Liang J, Hong J, et al
    Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis.
    PLoS One. 2020;15:e0233702.
    >> Share

  143. LIN WC, Lin YS, Chang CW, Chang CW, et al
    Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma.
    PLoS One. 2020;15:e0233212.
    >> Share

  144. MORISHITA N, Sakamori R, Yamada T, Kai Y, et al
    Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
    PLoS One. 2020;15:e0234811.
    >> Share

  145. STEFFEN G, Sperle I, Leendertz SA, Sarma N, et al
    The epidemiology of Hepatitis B, C and D in Germany: A scoping review.
    PLoS One. 2020;15:e0229166.
    >> Share

  146. DURACINSKY M, Thonon F, Bun S, Ben Nasr I, et al
    Good acceptability of HIV, HBV, and HCV screening during immigration medical check-up amongst migrants in France in the STRADA study.
    PLoS One. 2020;15:e0235260.
    >> Share


  147. Retraction: Hepatitis C Virus Core Protein Down-Regulates p21Waf1/Cip1 and Inhibits Curcumin-Induced Apoptosis through MicroRNA-345 Targeting in Human Hepatoma Cells.
    PLoS One. 2020;15:e0235375.
    >> Share

  148. BRAIN D, Mitchell J, O'Beirne J
    Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care.
    PLoS One. 2020;15:e0234577.
    >> Share

  149. LEE MH, Lee GA, Lee SH, Park YH, et al
    A systematic review on the causes of the transmission and control measures of outbreaks in long-term care facilities: Back to basics of infection control.
    PLoS One. 2020;15:e0229911.
    >> Share

  150. TRAEGER MW, Pedrana AE, van Santen DK, Doyle JS, et al
    The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.
    PLoS One. 2020;15:e0235445.
    >> Share

  151. ZHANG Y, Gao Z, Wang S, Liu J, et al
    Hepatitis C virus genotype/subtype distribution and evolution among Chinese blood donors: Revealing recent viral expansion.
    PLoS One. 2020;15:e0235612.
    >> Share

  152. COPPOCK D, Chou E, Gracely E, Gross R, et al
    Hepatitis C antibody screening and determinants of initial and duplicate screening in the baby boomer patients of six urban primary care clinics.
    PLoS One. 2020;15:e0235778.
    >> Share

  153. TRONINA O, Gotlib J, Malkowski P, Jaworski M, et al
    Translation and validation study of the Polish version of the Brief Hepatitis C Knowledge Scale.
    PLoS One. 2020;15:e0235764.
    >> Share

  154. LI H, Marks KM, Talal AH, van Seggelen WO, et al
    Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencing.
    PLoS One. 2020;15:e0235237.
    >> Share

  155. TRAN HTL, Morikawa K, Anggakusuma, Zibi R, et al
    OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease.
    PLoS One. 2020;15:e0236447.
    >> Share

  156. PEREIRA FM, Almeida MDCC, Santos FLN, Carreiro RP, et al
    Distribution of Human T-Lymphotropic Virus (HTLV) and Hepatitis C Co-infection in Bahia, Brazil.
    PLoS One. 2020;15:e0223087.
    >> Share

  157. SHAWON MA, Yousuf MAK, Raheem E, Ahmed S, et al
    Epidemiology, clinical features, and impact of food habits on the risk of hepatocellular carcinoma: A case-control study in Bangladesh.
    PLoS One. 2020;15:e0232121.
    >> Share

  158. SAITO K, Fukasawa M, Shirasago Y, Suzuki R, et al
    Comparative characterization of flavivirus production in two cell lines: Human hepatoma-derived Huh7.5.1-8 and African green monkey kidney-derived Vero.
    PLoS One. 2020;15:e0232274.
    >> Share

  159. PALAYEW A, Stumo SR, Cooke GS, Hutchinson SJ, et al
    The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data.
    PLoS One. 2020;15:e0235715.
    >> Share

  160. NGWAGA T, Kong L, Lin D, Schoborg C, et al
    Diversity of the hepatitis C virus NS5B gene during HIV co-infection.
    PLoS One. 2020;15:e0237162.
    >> Share

  161. TABU K, Mawatari S, Oda K, Kumagai K, et al
    Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
    PLoS One. 2020;15:e0237475.
    >> Share

  162. YEN HH, Su PY, Zeng YH, Liu IL, et al
    Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting.
    PLoS One. 2020;15:e0237582.
    >> Share

  163. BOBARDT M, Hansson MJ, Mayo P, Ure D, et al
    Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice.
    PLoS One. 2020;15:e0237236.
    >> Share

  164. JEPKEMEI KB, Ochwoto M, Swidinsky K, Day J, et al
    Characterization of occult hepatitis B in high-risk populations in Kenya.
    PLoS One. 2020;15:e0233727.
    >> Share

  165. RUIZ-EXTREMERA A, Diaz-Alcazar MDM, Munoz-Gamez JA, Cabrera-Lafuente M, et al
    Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission.
    PLoS One. 2020;15:e0233528.
    >> Share

  166. FAGUNDES RN, Ferreira LEVVC, Pace FHL
    Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free.
    PLoS One. 2020;15:e0237005.
    >> Share

  167. ASHHAB AA, Rodin H, Campos M, Abu-Sulb A, et al
    Response to hepatitis B virus vaccination in individuals with chronic hepatitis C virus infection.
    PLoS One. 2020;15:e0237398.
    >> Share

  168. DUCHESNE L, Hejblum G, Njouom R, Toure Kane C, et al
    Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in Central and Western Africa.
    PLoS One. 2020;15:e0238035.
    >> Share

  169. WALDENSTROM J, Nystrom K, Nilsson S, Norkrans G, et al
    The relation of 25-hydroxy vitamin D concentrations to liver histopathology, seasonality and baseline characteristics in chronic hepatitis C virus genotype 2 or 3 infection.
    PLoS One. 2020;15:e0237840.
    >> Share

  170. CABEZAS C, Trujillo O, Gonzales-Vivanco A, Benites Villafane CM, et al
    Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study.
    PLoS One. 2020;15:e0234273.
    >> Share

  171. ANDERSON ES, Russell C, Basham K, Montgomery M, et al
    High prevalence of injection drug use and blood-borne viral infections among patients in an urban emergency department.
    PLoS One. 2020;15:e0233927.
    >> Share

  172. NIELSEN S, Hansen JF, Hay G, Cowan S, et al
    Hepatitis C prevalence in Denmark in 2016-An updated estimate using multiple national registers.
    PLoS One. 2020;15:e0238203.
    >> Share

  173. READY E, Habecker P, Abadie R, Khan B, et al
    Competing forces of withdrawal and disease avoidance in the risk networks of people who inject drugs.
    PLoS One. 2020;15:e0235124.
    >> Share

  174. ASEMAHAGN MA
    Epidemiology of hepatitis B and C virus infections among patients who booked for surgical procedures at Felegehiwot referral hospital, Northwest Ethiopia.
    PLoS One. 2020;15:e0234822.
    >> Share

  175. LI J, Abosmaha E, Coffin CS, Labonte P, et al
    Reticulon-3 modulates the incorporation of replication competent hepatitis C virus molecules for release inside infectious exosomes.
    PLoS One. 2020;15:e0239153.
    >> Share

  176. JARGALSAIKHAN G, Eichner M, Boldbaatar D, Bat-Ulzii P, et al
    Sensitivity and specificity of commercially available rapid diagnostic tests for viral hepatitis B and C screening in serum samples.
    PLoS One. 2020;15:e0235036.
    >> Share

  177. GANDJOUR A
    Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.
    PLoS One. 2020;15:e0236543.
    >> Share

  178. OYAMA M, Ohnuki Y, Inoue M, Uruha A, et al
    HLA-DRB1 allele and autoantibody profiles in Japanese patients with inclusion body myositis.
    PLoS One. 2020;15:e0237890.
    >> Share

  179. AMORAS EDSG, Monteiro Gomes ST, Freitas Queiroz MA, de Araujo MSM, et al
    Intrahepatic interleukin 10 expression modulates fibrinogenesis during chronic HCV infection.
    PLoS One. 2020;15:e0241199.
    >> Share

  180. GALLACH M, Vergara M, Pedro da Costa J, Miquel M, et al
    Correction: Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C.
    PLoS One. 2020;15:e0241559.
    >> Share

  181. CARDONA-ARIAS JA, Correa JCC, Higuita-Gutierrez LF
    Prevalence of hepatitis B/C viruses and associated factors in key groups attending a health services institution in Colombia, 2019.
    PLoS One. 2020;15:e0238655.
    >> Share

  182. HAGA H, Sato H, Koseki A, Saito T, et al
    A machine learning-based treatment prediction model using whole genome variants of hepatitis C virus.
    PLoS One. 2020;15:e0242028.
    >> Share

  183. JAVANBAKHT M, Archer R, Klausner J
    Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system.
    PLoS One. 2020;15:e0241615.
    >> Share

  184. SEMMO N, Mullhaupt B, Ruckstuhl L, Magenta L, et al
    A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naive patients suffering from fatigue and receiving 3D regimen: The HEMATITE study.
    PLoS One. 2020;15:e0241267.
    >> Share

  185. LEE JJ, Wei YJ, Lin MY, Niu SW, et al
    The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C.
    PLoS One. 2020;15:e0242601.
    >> Share

  186. PAPALUCA T, Craigie A, McDonald L, Edwards A, et al
    Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C.
    PLoS One. 2020;15:e0242101.
    >> Share

  187. JIANG K, Mohammad MK, Dar WA, Kong J, et al
    Quantitative assessment of liver fibrosis by digital image analysis reveals correlation with qualitative clinical fibrosis staging in liver transplant patients.
    PLoS One. 2020;15:e0239624.
    >> Share

  188. PATIL S, Rao A, Pathak P, Kurle S, et al
    Unsterile injection equipment associated with HIV outbreak and an extremely high prevalence of HCV-A case-control investigation from Unnao, India.
    PLoS One. 2020;15:e0243534.
    >> Share

  189. VETTER BN, Ongarello S, Tyshkovskiy A, Alkhazashvili M, et al
    Sensitivity and specificity of rapid hepatitis C antibody assays in freshly collected whole blood, plasma and serum samples: A multicentre prospective study.
    PLoS One. 2020;15:e0243040.
    >> Share

  190. AKIYAMA MJ, Ross J, Rimawi F, Fox A, et al
    Knowledge, attitudes, and acceptability of direct-acting antiviral hepatitis C treatment among people incarcerated in jail: A qualitative study.
    PLoS One. 2020;15:e0242623.
    >> Share

  191. SAZZAD HMS, McCredie L, Treloar C, Lloyd AR, et al
    Violence and hepatitis C transmission in prison-A modified social ecological model.
    PLoS One. 2020;15:e0243106.
    >> Share

  192. SOHOLM J, Hansen JF, Mossner B, Roge BT, et al
    Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
    PLoS One. 2020;15:e0243725.
    >> Share

  193. ABE K, Wakabayashi H, Nakayama H, Suzuki T, et al
    Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis.
    PLoS One. 2020;15:e0243473.
    >> Share

  194. BEKKI S, Hashimoto S, Yamasaki K, Komori A, et al
    Serum kynurenine levels are a novel biomarker to predict the prognosis of patients with hepatocellular carcinoma.
    PLoS One. 2020;15:e0241002.
    >> Share

  195. PEARCE ME, Yu A, Alvarez M, Bartlett SR, et al
    Prenatal hepatitis C screening, diagnoses, and follow-up testing in British Columbia, 2008-2019.
    PLoS One. 2020;15:e0244575.
    >> Share

  196. KHLAIPHUENGSIN A, Chuaypen N, Sodsai P, Reantragoon R, et al
    Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection.
    PLoS One. 2020;15:e0244112.
    >> Share

  197. MIGITA K, Nakamura M, Aiba Y, Kozuru H, et al
    Association of soluble T cell immunoglobulin domain and mucin-3 (sTIM-3) and mac-2 binding protein glycosylation isomer (M2BPGi) in patients with autoimmune hepatitis.
    PLoS One. 2020;15:e0238540.
    >> Share

  198. POURCHER V, Gourmelen J, Bureau I, Bouee S, et al
    Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France.
    PLoS One. 2020;15:e0243529.
    >> Share

  199. LAWAL MA, Adeniyi OF, Akintan PE, Salako AO, et al
    Prevalence of and risk factors for hepatitis B and C viral co-infections in HIV infected children in Lagos, Nigeria.
    PLoS One. 2020;15:e0243656.
    >> Share

    January 2019
  200. MANGIA A, Piazzolla V, Giannelli A, Visaggi E, et al
    Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
    PLoS One. 2019;14:e0223287.
    >> Share

  201. LONDONO MC, Riveiro-Barciela M, Ahumada A, Munoz-Gomez R, et al
    Effectiveness, safety/tolerability of OBV/PTV/r +/- DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
    PLoS One. 2019;14:e0221567.
    >> Share

  202. GARCIA A, Moore Boffi S, Gayet-Ageron A, Vernaz N, et al
    Access to unauthorized hepatitis C generics: Perception and knowledge of physicians, pharmacists, patients and non-healthcare professionals.
    PLoS One. 2019;14:e0223649.
    >> Share

  203. RAYAN DA'AS S, Azzeh M
    Subgenotyping and genetic variability of hepatitis C virus in Palestine.
    PLoS One. 2019;14:e0222799.
    >> Share

  204. KUO YH, Kee KM, Hsu NT, Wang JH, et al
    Using AST-platelet ratio index and fibrosis 4 index for detecting chronic hepatitis C in a large-scale community screening.
    PLoS One. 2019;14:e0222196.
    >> Share

  205. BRENNER N, Mentzer AJ, Butt J, Braband KL, et al
    Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.
    PLoS One. 2019;14:e0210407.
    >> Share

  206. GARDINI I, Bartoli M, Conforti M, Mennini FS, et al
    Estimation of the number of HCV-positive patients in Italy.
    PLoS One. 2019;14:e0223668.
    >> Share

  207. MOHD SUAN MA, Said SM, Lim PY, Azman AZF, et al
    Risk factors for hepatitis C infection among adult patients in Kedah state, Malaysia: A case-control study.
    PLoS One. 2019;14:e0224459.
    >> Share

  208. BLACKARD JT, Kong L, Rouster SD, Karns R, et al
    CCR5 receptor antagonism inhibits hepatitis C virus (HCV) replication in vitro.
    PLoS One. 2019;14:e0224523.
    >> Share

  209. ZHENG Z, Lin J, Lu Z, Su J, et al
    Mortality risk in the population of HIV-positive individuals in Southern China: A cohort study.
    PLoS One. 2019;14:e0210856.
    >> Share

  210. MANUEL SOUSA J, Vergara M, Pulido F, Sanchez Antolin G, et al
    Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r +/- dasabuvir +/- ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
    PLoS One. 2019;14:e0225061.
    >> Share

  211. ZUCKERMAN AD, Douglas A, Whelchel K, Choi L, et al
    Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
    PLoS One. 2019;14:e0225434.
    >> Share

  212. HAMADEH A, Feng Z, Krahn M, Wong WWL, et al
    A model-based framework for chronic hepatitis C prevalence estimation.
    PLoS One. 2019;14:e0225366.
    >> Share

  213. SHENGE JA, Odaibo GN, Olaleye DO
    Correction: Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria.
    PLoS One. 2019;14:e0225679.
    >> Share

  214. MUCKE MM, Maasoumy B, Dietz J, Mucke VT, et al
    Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy.
    PLoS One. 2019;14:e0224751.
    >> Share


  215. Retraction: Pathological Roles of Interleukin-22 in the Development of Recurrent Hepatitis C after Liver Transplantation.
    PLoS One. 2019;14:e0225971.
    >> Share

  216. PAGE K, Evans JL, Hahn JA, Vickerman P, et al
    HCV incidence is associated with injecting partner age and HCV serostatus mixing in young adults who inject drugs in San Francisco.
    PLoS One. 2019;14:e0226166.
    >> Share

  217. FILHO HRM, Bierrenbach ALS, Capuani MLD, Mendrone A Jr, et al
    Impact on mortality of being seropositive for hepatitis C virus antibodies among blood donors in Brazil: A twenty-year study.
    PLoS One. 2019;14:e0226566.
    >> Share

  218. SHIFERAW E, Tadilo W, Melkie I, Shiferaw M, et al
    Sero-prevalence and trends of transfusion-transmissible infections among blood donors at Bahir Dar district blood bank, northwest Ethiopia: A four year retrospective study.
    PLoS One. 2019;14:e0214755.
    >> Share

  219. BOATENG R, Mutocheluh M, Dompreh A, Obiri-Yeboah D, et al
    Sero-prevalence of Hepatitis B and C viral co-infections among HIV-1 infected ART-naive individuals in Kumasi, Ghana.
    PLoS One. 2019;14:e0215377.
    >> Share

  220. MORRIS MD, Andrew E, Tan JY, Maher L, et al
    Injecting-related trust, cooperation, intimacy, and power as key factors influencing risk perception among drug injecting partnerships.
    PLoS One. 2019;14:e0217811.
    >> Share

  221. CHENG YW, Chang YC, Chen YL, Chen RC, et al
    Feasibility of measuring spleen stiffness with MR elastography and splenic volume to predict hepatic fibrosis stage.
    PLoS One. 2019;14:e0217876.
    >> Share

  222. ROBERTS H, Boktor SW, Waller K, Daar ZS, et al
    Underreporting of Hepatitis B and C virus infections - Pennsylvania, 2001-2015.
    PLoS One. 2019;14:e0217455.
    >> Share

  223. FREMPONG MT, Ntiamoah P, Annani-Akollor ME, Owiredu WKBA, et al
    Hepatitis B and C infections in HIV-1 and non-HIV infected pregnant women in the Brong-Ahafo Region, Ghana.
    PLoS One. 2019;14:e0219922.
    >> Share

  224. YEN YH, Chen CH, Hung CH, Wang JH, et al
    Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data.
    PLoS One. 2019;14:e0222605.
    >> Share

  225. O'CONNOR SM, Mixson-Hayden T, Ganova-Raeva L, Djibo DA, et al
    Integrated HIV surveillance finds recent adult hepatitis B virus (HBV) transmission and intermediate HBV prevalence among military in uncharacterized Caribbean country.
    PLoS One. 2019;14:e0222835.
    >> Share

  226. KUNISHIMA H, Yoshida E, Caputo J, Mikamo H, et al
    Estimating the national cost burden of in-hospital needlestick injuries among healthcare workers in Japan.
    PLoS One. 2019;14:e0224142.
    >> Share

  227. GALLAY P, Ure D, Bobardt M, Chatterji U, et al
    The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice.
    PLoS One. 2019;14:e0217433.
    >> Share

  228. WOLDEGIORGIS AE, Erku W, Medhin G, Berhe N, et al
    Community-based sero-prevalence of hepatitis B and C infections in South Omo Zone, Southern Ethiopia.
    PLoS One. 2019;14:e0226890.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016